Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
475 Leser
Artikel bewerten:
(2)

POPLAR CREEK RESOURCES INC. - Amended Announcement of Resignation of Auditor

Finanznachrichten News

CALGARY, AB / ACCESSWIRE / June 13, 2024 / Poplar Creek Resources Inc. (the "Corporation") announces that Buchannan Barry LLP (the "Predecessor Auditor") has resigned as auditor of the Corporation. The Change of Auditor Notice (the "Notice") delivered by the Corporation to the Predecessor Auditor stated that:

i. the Predecessor Auditor resigned on its own initiative;
ii. the resignation of the Predecessor Auditor was considered by the Corporation's board of directors;
iii. the Predecessor Auditor's reports on the Corporation's annual financial statements relating to the period commencing at the beginning of the Corporation's two most recently completed financial years, being the years ending December 31, 2021 and December 31, 2022 and ending on the Date of Resignation did not express a modified opinion
iv. and there are no reportable events.

In an amended response dated June 7, 2024, the Predecessor Auditor confirmed that it had reviewed the Notice and, based on its knowledge of such information at that time, it agreed with the information contained in the Notice except as set out below.

The Predecessor Auditor stated that they disagreed with clause (e) in the Notice that there is no reportable event. It is their view that there is a reportable event as there is an unresolved issue that, in their opinion, has, or could have, a material impact on the financial statements, or reports provided by them relating to the financial statements for any financial period during the period commencing at the beginning of the Corporation's two most recently completed financial years and ending on the date of its resignation, and about which it has advised the Corporation that the matter was not resolved to their satisfaction before the date of resignation. Specifically:

  1. An option agreement (the "Option") had been terminated by the owner of the Option lands, which termination had not been accounted for in the Corporation's draft Q4 financial statements, and which led them to be concerned over the reliability of the financial statement presentation and disclosures provided to them.
  2. The termination of the Option had also not been accounted for in the December 31, 2023 audited financial statements of the Corporation's subsidiary Zambezi Rainbow Minerals ("ZRM"), which caused them concern regarding the reliability of the ZRM audited financial statements as their work relies on the audited financial statements of the subsidiary.
  3. They were advised by the Corporation that it had been over a year since access to the land surface on a property option had been denied, which led them to be concerned over whether that intangible asset was impaired to a value materially different than stated on the draft Q4 financial statements.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Richard Edgar
President and Chief Executive Officer
Telephone: (403) 616-5387
Email: redgarex@gmail.com

SOURCE: Poplar Creek Resources Inc.



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.